Cardiovascular effects of Roflumilast during sepsis: Risks or benefits?

Area of Science:

• Cardiovascular Physiology
• Pharmacology
• Inflammation Research

Background:

• Phosphodiesterase-4 (PDE4) regulates cyclic adenosine monophosphate (cAMP) signaling.
• PDE4 inhibitors like roflumilast (RFM) possess anti-inflammatory properties.
• The impact of RFM on sepsis-induced cardiovascular dysfunction remains largely unexplored.

Purpose of the Study:

• To investigate the effects of RFM on cardiovascular collapse in sepsis.
• To assess RFM's influence on multiorgan damage during sepsis.

Main Methods:

• Sepsis was induced in rats via cecal ligation and puncture (CLP).
• Animals received either RFM (0.3 mg/kg) or vehicle subcutaneously 6 hours post-CLP.
• Cardiovascular parameters, organ damage, and plasma markers were evaluated 24 hours after CLP.

Main Results:

• Sepsis caused hypotension, tachycardia, reduced renal blood flow (RBF), and hyporeactivity to vasoconstrictors.
• RFM increased systemic cAMP and RBF, attenuated liver hypoperfusion and damage, and reduced nitric oxide (NO) levels.
• RFM exacerbated hypotension and tachycardia in septic rats, without improving vascular hyporeactivity.

Conclusions:

• PDE4 inhibition with RFM demonstrates protective effects against hepatic injury and improves renal perfusion in sepsis.
• Despite anti-inflammatory benefits, RFM worsened hemodynamic instability and did not protect against sepsis-induced cardiovascular dysfunction or mortality.
• Cautious application of RFM in sepsis is recommended due to its adverse effects on cardiovascular parameters.